Kumar M, Alter B P
University of Texas Medical Branch at Galveston, Division of Pediatric Hematology/Oncology, Children's Hospital 77555-0361, USA.
Curr Opin Hematol. 1998 May;5(3):226-34. doi: 10.1097/00062752-199805000-00014.
The use of hematopoietic growth factors, although well established for the management of chemotherapy-induced neutropenia, remains controversial for the treatment of aplastic anemia and inherited bone marrow failure syndromes. The most commonly used factors are granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin. Newer growth factors such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising results in the laboratory, and some have been used in clinical trials. This article reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited bone marrow failure, and discusses emerging concerns about long term toxicity of these factors.
造血生长因子用于化疗所致中性粒细胞减少的治疗虽已得到充分确立，但在再生障碍性贫血和遗传性骨髓衰竭综合征的治疗中仍存在争议。最常用的因子是粒细胞集落刺激因子、粒细胞巨噬细胞集落刺激因子和促红细胞生成素。较新的生长因子如干细胞因子、血小板生成素、Flt3配体和白细胞介素在实验室已显示出有前景的结果，并且有些已用于临床试验。本文综述了新旧造血生长因子在获得性和遗传性骨髓衰竭中的临床应用，并讨论了对这些因子长期毒性的新关注。
